---
title: "Harrow, Inc. (HROW.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HROW.US.md"
symbol: "HROW.US"
name: "Harrow, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-01T23:00:02.220Z"
locales:
  - [en](https://longbridge.com/en/quote/HROW.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HROW.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HROW.US.md)
---

# Harrow, Inc. (HROW.US)

## Company Overview

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.harrow.com](https://www.harrow.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-01T04:30:17.000Z

**Overall: C (0.52)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 61 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 36.41% |  |
| Net Profit YoY | 70.60% |  |
| P/B Ratio | 28.77 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1508919943.65 |  |
| Revenue | 272303000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.42% | D |
| Profit Margin | -1.89% | D |
| Gross Margin | 75.05% | A |
| Revenue YoY | 36.41% | A |
| Net Profit YoY | 70.60% | A |
| Total Assets YoY | 2.70% | C |
| Net Assets YoY | -24.83% | E |
| Cash Flow Margin | -853.55% | E |
| OCF YoY | 36.41% | A |
| Turnover | 0.69 | B |
| Gearing Ratio | 86.96% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Harrow, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "36.41%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "70.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "28.77",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1508919943.65",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "272303000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.42%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1.89%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "75.05%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "36.41%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "70.60%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.70%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-24.83%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-853.55%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "36.41%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.69",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "86.96%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -293.62 | 228/183 | - | - | - |
| PB | 28.77 | 187/183 | 36.05 | 28.49 | 20.65 |
| PS (TTM) | 5.54 | 101/183 | 7.01 | 6.04 | 5.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 02 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 03 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 04 | Novo Nordisk AS (NVO.US) | A | B | B | D | B | B |
| 05 | GSK (GSK.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-16T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 40.90 |
| Highest Target | 91.00 |
| Lowest Target | 59.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HROW.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HROW.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HROW.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HROW.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**